CN113841737A - Application of lactobacillus reuteri strain derived from breast milk to prevention and treatment of atopic dermatitis - Google Patents
Application of lactobacillus reuteri strain derived from breast milk to prevention and treatment of atopic dermatitis Download PDFInfo
- Publication number
- CN113841737A CN113841737A CN202111233636.7A CN202111233636A CN113841737A CN 113841737 A CN113841737 A CN 113841737A CN 202111233636 A CN202111233636 A CN 202111233636A CN 113841737 A CN113841737 A CN 113841737A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus reuteri
- atopic dermatitis
- product
- treatment
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012438 Dermatitis atopic Diseases 0.000 title claims abstract description 59
- 241000186604 Lactobacillus reuteri Species 0.000 title claims abstract description 59
- 201000008937 atopic dermatitis Diseases 0.000 title claims abstract description 59
- 229940001882 lactobacillus reuteri Drugs 0.000 title claims abstract description 59
- 230000002265 prevention Effects 0.000 title claims abstract description 7
- 235000020256 human milk Nutrition 0.000 title abstract description 4
- 210000004251 human milk Anatomy 0.000 title abstract description 4
- 241000699670 Mus sp. Species 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 10
- 235000013305 food Nutrition 0.000 claims description 10
- 210000003630 histaminocyte Anatomy 0.000 claims description 9
- 235000013361 beverage Nutrition 0.000 claims description 8
- 210000003979 eosinophil Anatomy 0.000 claims description 8
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 8
- 230000006651 lactation Effects 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 230000008961 swelling Effects 0.000 claims description 6
- 230000035935 pregnancy Effects 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims description 4
- 230000004151 fermentation Effects 0.000 claims description 4
- 206010020718 hyperplasia Diseases 0.000 claims description 4
- 230000008595 infiltration Effects 0.000 claims description 4
- 238000001764 infiltration Methods 0.000 claims description 4
- 210000004969 inflammatory cell Anatomy 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 229940069428 antacid Drugs 0.000 claims description 2
- 239000003159 antacid agent Substances 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 235000013365 dairy product Nutrition 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims description 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000001575 pathological effect Effects 0.000 abstract description 6
- 206010014025 Ear swelling Diseases 0.000 abstract description 5
- 208000037852 mild atopic dermatitis Diseases 0.000 abstract description 5
- 244000005700 microbiome Species 0.000 abstract description 2
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 32
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 32
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 22
- 229960002882 calcipotriol Drugs 0.000 description 21
- 201000004624 Dermatitis Diseases 0.000 description 14
- 239000006041 probiotic Substances 0.000 description 10
- 235000018291 probiotics Nutrition 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000003304 gavage Methods 0.000 description 9
- 230000000529 probiotic effect Effects 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 240000001307 Myosotis scorpioides Species 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 235000015140 cultured milk Nutrition 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 239000003862 glucocorticoid Substances 0.000 description 4
- 235000020185 raw untreated milk Nutrition 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000000222 eosinocyte Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 1
- 244000085464 Capparis decidua Species 0.000 description 1
- 235000017623 Capparis decidua Nutrition 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 206010024438 Lichenification Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 206010037083 Prurigo Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000020122 reconstituted milk Nutrition 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 125000005628 tolylene group Chemical group 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/366—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/70—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter
- A23L2/84—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter using microorganisms or biological material, e.g. enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Agronomy & Crop Science (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses an application of lactobacillus reuteri from breast milk in prevention and treatment of atopic dermatitis, and belongs to the technical field of microorganisms and medicines. The invention provides a new application of lactobacillus reuteri FN041 in preventing and/or treating atopic dermatitis, which can prevent the occurrence of the atopic dermatitis of mice and improve the ear swelling degree and the skin pathological symptoms of the mice; significantly reduces the score of SCORAD in children with mild atopic dermatitis. Therefore, the lactobacillus reuteri FN041 has huge application prospect in preparing products for preventing and/or treating children atopic dermatitis.
Description
Technical Field
The invention relates to an application of lactobacillus reuteri from breast milk in prevention and treatment of atopic dermatitis, and belongs to the technical field of microorganisms and medicines.
Background
Atopic Dermatitis (AD) is a chronic, recurrent, inflammatory skin disease in which more than about 60% of patients develop early infancy, mostly within 2 years of age, and persist into adolescence, even after adulthood. Severe itching of infant skin caused by AD seriously affects sleeping and growth development; with the development of the allergic process, children are also susceptible to asthma, allergic rhinitis and conjunctivitis. With the progress of urbanization and social development, in recent years, the incidence rate of skin and respiratory diseases caused by allergy in China is obviously increased, the prevalence rate of atopic dermatitis of urban children of 1 to 7 years old in China is up to 12.94%, and the prevalence rate of AD of infants in 1 to 12 months is up to 30.48%. The increasing prevalence severely impacts the quality of life for patients and families. The pathogenesis of atopic dermatitis has been established due to an immune imbalance between helper T cells 1(Th1) and helper T cells 2(Th2) in patients and the development of immune tolerance not established during the immune development window.
At the present stage, there is no therapeutic drug with definite therapeutic effect against AD. Therefore, at present, mainly: 1) anti-inflammatory effects are exerted by external drugs such as glucocorticoids and calcineurin inhibitors; 2) external zinc oxide oil (paste) preparation, black soybean distillate oil ointment, physiological sodium chloride solution and other wet-applied medicines or phosphodiesterase 4 for caring skin or preventing body fluid exudation; 3) systemic administration, including oral antihistamine, immunosuppressant, low-dose systemic glucocorticoid, biological preparation such as interleukin 4(IL-4)/13 receptor a chain fully human monoclonal antibody, Janus kinase inhibitor, etc.; 4) topically or systemically performing antibacterial, antiviral or antifungal treatment.
However, the above drugs have great adverse reactions, and most patients have concerns about hormone drugs, and are not suitable for direct application to infants, which all bring great difficulties to AD treatment. Meanwhile, the method brings great trouble to the life of patients and families. In addition, current therapeutic measures are mainly used for improving symptoms, but cannot regulate the immune balance of patients, and cannot fundamentally improve the allergic constitution of the patients. Thus, there is still a need for a medicament or treatment which is suitable for infant patients without side effects to the patient, which can be used to combat the onset of allergies and the development of skin inflammation, and which can be applied to various classes of patients.
Disclosure of Invention
The invention discovers that the lactobacillus reuteri FN041 has the effect of relieving atopic dermatitis, so the invention provides the application of the lactobacillus reuteri FN041 in preparing a product for preventing and/or treating the atopic dermatitis of a target population; the target population is pregnant women, lactating women and/or children.
In one embodiment, lactobacillus reuteri FN041 is disclosed in the patent publication with publication No. CN 110205261A.
In one embodiment, the prevention and/or treatment of atopic dermatitis comprises any one of (a) to (d):
(a) relieving inflammatory reaction and inflammatory hyperplasia;
(b) relieving the swelling degree of the affected part;
(c) reducing the number of mast cells and eosinophils;
(d) improve the infiltration degree of inflammatory cells of the mice.
In one embodiment, the gestational period is from week 14 of gestation until the infant is born.
In one embodiment, the lactation period is within 12 months from birth of the infant.
In one embodiment, the target child is no older than 12 years; preferably, the target child is no older than 8 years.
In one embodiment, the atopic dermatitis is mild atopic dermatitis, specifically atopic dermatitis having a skin lesion area of less than or equal to 40% of the body surface area.
In one embodiment, the product includes, but is not limited to, a food product, a pharmaceutical or pharmaceutical composition, and/or a nutraceutical.
In one embodiment, the product has a viable count of not less than 1 × 106CFU/day doses were given to children; preferably, the number of viable bacteria is 1X 109CFU/day doses were given to children.
In one embodiment, the form of lactobacillus reuteri comprises the form of viable cells, inactivated cells or fermentation products or metabolites of lactobacillus reuteri, or a mixture of any of the above forms.
In one embodiment, the lactobacillus reuteri is present in the product in an amount of not less than 1 x 104CFU/mL or 1X 104CFU/g。
In one embodiment, the dosage form of the product includes, but is not limited to: tablet, granule, capsule, powder, liquid or jelly.
In one embodiment, the medicament or pharmaceutical composition further comprises a pharmaceutically acceptable excipient; the pharmaceutically acceptable excipient refers to any diluent, adjuvant and/or carrier that can be used in the pharmaceutical field.
In one embodiment, the food product comprises a dairy product, a soy product, a fruit and vegetable product or a beverage produced using a lactobacillus reuteri-containing starter; or the food comprises a solid beverage, tablet, soft candy and drops containing the lactobacillus reuteri.
In one embodiment, the food and health care product further comprises conventional auxiliary materials, wherein the auxiliary materials comprise one or more of fillers, flavoring agents, binders, disintegrating agents, lubricants, antacids and nutrition enhancers.
The invention has the beneficial effects that:
the invention provides a new application of lactobacillus reuteri FN041 in preventing and/or treating atopic dermatitis, has good effect and has great application prospect in preparing products for preventing and/or treating atopic dermatitis.
Animal experiments show that:
(1) the female mouse takes the lactobacillus reuteri FN041 in the gestation period and the lactation period to prevent the offspring from generating atopic dermatitis, which is shown as obviously improving the ear swelling degree and the skin pathological symptoms of the weaned offspring mouse;
(2) the female mouse takes the lactobacillus reuteri FN041 in the gestation period and the lactation period, and the offspring mouse also takes the lactobacillus reuteri FN041, so that the swelling degree and the skin pathological symptoms of the offspring mouse can be improved;
(3) administration of lactobacillus reuteri FN041 to young offspring mice significantly improved the degree of ear swelling and the skin pathology.
Human body experiments show that:
after the probiotic powder containing lactobacillus reuteri FN041 is taken by children suffering from mild atopic dermatitis, the SCORAD index of the children suffering from mild atopic dermatitis can be remarkably reduced.
Drawings
FIG. 1 is a design of an experiment; mice were treated with Lactobacillus reuteri FN041 or Lactobacillus rhamnosus GG (1X 10) daily gavage in late gestation and lactation9CFU/day), right ear of mice was swabbed with MC903 after weaning, inducing atopic dermatitis. GDMCC60546, lactobacillus reuteri FN 041; LGG, lactobacillus rhamnosus GG; MC903, calcipotriol.
FIG. 2 is a graph showing the effect of probiotic intake in the mother mice in preventing the offspring from developing atopic dermatitis; gdmcc60546 treatment significantly prevented the progeny mice from inducing ear redness by MC 903; daily ear thickness of mice after MC903 treatment; thickness of mouse ear relative to normal control at the end of mc903 treatment; GDMCC60546, lactobacillus reuteri FN 041; LGG, lactobacillus rhamnosus GG; MC903, calcipotriol.
FIG. 3 is a pathological feature of an ear section of an atopic dermatitis mouse; A. typical pathology pictures of hematoxylin-eosin stain, mast cell stain (tolylene olive blue stain), or eosinophil (Carbol 2R stain); B. the content of mast cells in unit area of the pathological section; C. eosinophil content per unit area of pathological section; GDMCC60546 is Lactobacillus reuteri FN 041; LGG is Lactobacillus rhamnosus GG; MC903 is calcipotriol.
FIG. 4 is a flow chart of the SCORAD index clinical trial for atopic dermatitis patients.
FIG. 5 is a graph comparing the effect of different groups on lowering the SCORAD index in patients with mild atopic dermatitis.
Detailed Description
The invention is further illustrated with reference to specific examples.
The enzyme-hydrolyzed skim milk, glucose, tryptone and yeast extract mentioned in the examples below were purchased from Shanghai pharmaceutical group, Inc.
The detection methods referred to in the following examples are as follows:
the detection method of viable count comprises the following steps: the national standard GB 4789.35-2016 food safety national standard food microbiology detection of lactobacillus is adopted.
Lactobacillus reuteri FN041 used in the examples described below is disclosed in patent publication No. CN 110205261A.
Example i: effect of Lactobacillus reuteri FN041 on ear thickness in atopic dermatitis mice
Male and female BALB/C mice (2: 1 by number) 7 weeks old were housed in polypropylene cages, after female conception, the males were removed from the cages and the females were randomly divided into 4 groups, each: blank group (Control), MC903 dermatitis-inducing group (AD), MC903 dermatitis-inducing and gavage Lactobacillus reuteri FN041 group (AD + GDMCC60546), and MC903 dermatitis-inducing and gavage Lactobacillus rhamnosus GG group (AD + LGG), wherein the AD + GDMCC60546 group and the AD + LGG group are both treatment groups.
Gavage treatment was started one week before birth of pregnant mice: lavage PBS (1X 10) for blank group and MC903 induced dermatitis group9CFU/day, 1 time per day, 100 μ L each time), AD + GDMCC60546 group per day gavage Lactobacillus reuteri FN041(1 × 10)9CFU/day, 1 time per day, 100 μ L each time), AD + LGG group, and Lactobacillus rhamnosus GG (1 × 10) for intragastric administration9CFU/day, 1 time per day, 100 μ L each) until the end of the 3-week lactation period.
After young offspring is weaned, the offspring atopic dermatitis is induced by MC903 for 7 days, the right ear of the offspring mouse is smeared with MC 90320 mu L every day, the left ear is controlled by the same amount of absolute ethyl alcohol, a blank group is not treated, meanwhile, the stomach irrigation treatment of the same mother mouse is also carried out on each group of the offspring, and all the groups are free drinking water and food intake. The experimental procedure described above can be seen in FIG. 1. The ear thickness of 4 groups of mice was measured with an electronic vernier caliper before the start of molding (i.e., day 0), and then the change in ear thickness was measured every day, and after the end of molding (i.e., day 8), the mice were photographed and sacrificed.
As can be seen from FIG. 2, the treatment groups of Lactobacillus reuteri FN041 and Lactobacillus rhamnosus GG significantly reduced the thickness of the ears of the mice in the model group and the degree of redness of the ears of the mice after the experiment (P < 0.05). Compared with the AD + LGG group, the Lactobacillus reuteri FN041 has larger reduction degree on the thickness of the mouse ear and stronger relieving capacity on the swelling degree of the mouse ear. On day 5 of treatment, GDMCC60546 treatment inhibited ear swelling in mice by up to 50%, 25% more than LGG. At day seven, GDMCC60546 maintained a 50% inhibition, 30% higher than LGG.
Example 2: effect of Lactobacillus reuteri FN041 on skin inflammation in atopic dermatitis mice
Male and female BALB/C mice (2: 1 by number) 7 weeks old were housed in polypropylene cages, after female conception, the males were removed from the cages and the females were randomly divided into 4 groups, each: blank group (Control), MC903 dermatitis-inducing group (AD), MC903 dermatitis-inducing and gavage Lactobacillus reuteri FN041 group (AD + Fn041), MC903 dermatitis-inducing and gavage Lactobacillus rhamnosus GG group (AD + LGG), wherein the AD + Fn041 group and the AD + LGG group are both treatment groups.
The gavage treatment, the placebo group and the MC903 induced dermatitis group were started one week before the birth of pregnant mice, and the gavage PBS (1X 10)9CFU/day, 1 time per day, 100 μ L each time), AD + Fn041 group was administered daily Lactobacillus reuteri FN041(1 × 10)9CFU/day, 1 time per day, 100 μ L each time), AD + LGG group, and Lactobacillus rhamnosus GG (1 × 10) for intragastric administration9CFU/day, 1 time per day, 100 μ L each) until the end of the 3-week lactation period.
After weaning of young offspring, offspring atopic dermatitis was induced with MC903 for a total of 7 days, right ear of offspring mice was smeared with MC 90320 μ L each day, left ear was controlled with equal amount of absolute ethanol, blank group was left untreated, all groups were free to drink and eat. The specific experimental flow is shown in figure 1. After completion of molding (i.e., day 8), blood was taken and the mice were sacrificed to prepare ear sections, which were subjected to eosin staining, mast cell staining (toluidine blue staining) and eosinophil staining (Carbol 2R staining), respectively.
As can be seen from FIG. 3, the structure of epidermal cells of ear skin of the mice in the blank group is normal, and inflammatory reaction does not occur in each layer of the epidermis; the pathology of the ear skin of the mice in the dermatitis group shows obvious inflammatory hyperplastic change, meanwhile, the red and swollen degree of the ears is increased, and the number of mast cells and eosinophilic granulocytes is obviously increased; the degree of redness of ear skin of mice treated by lactobacillus reuteri FN041 and lactobacillus rhamnosus GG is reduced, the inflammatory hyperplasia is relieved, the number of eosinophilic granulocytes and mast cells is obviously reduced, and the degree of redness of ear of the mice treated by lactobacillus reuteri FN041 is lighter and the inflammatory cell infiltration is less. MC903 induction increased mouse ear mast cells by about 2.3 times. After the treatment of GDMCC60546, the number of mast cells per square millimeter of the ear section can be reduced by 62 percent, while the LGG treatment can be reduced by only 56 percent. MC903 induction increased eosinophils in the mouse ear by about 12-fold, MC903 induction decreased eosinophils in the mouse ear sections by 67% per square millimeter, while LGG decreased eosinophils by 58%.
The experiments show that the ingestion of lactobacillus reuteri FN041 and LGG in the maternal generation can prevent the offspring mice from generating AD, can obviously relieve the ear swelling degree of atopic dermatitis model mice, and improve the infiltration degree of inflammatory cells of the mice, thereby effectively relieving the atopic dermatitis symptoms of the mice, and the effect of GDMCC60546 is better than that of LGG.
Example 3: effect of Lactobacillus reuteri FN041 on SCORAD index of atopic dermatitis patients in children of 4-7 years old
80 children with atopic dermatitis were recruited in this clinical trial, and all patients were randomized into 3 groups of three groups
Group A: placebo group (20 persons) taking maltodextrin,
group B: treatment group with Lactobacillus rhamnosus GG (LGG group) (25 persons),
group C: treatment group (GDMCC 60546) with Lactobacillus reuteri FN041 was administered (35 patients).
Wherein the product administered to the placebo group is maltodextrin which does not contain a probiotic component; the GDMCC60546 group is administered with Lactobacillus reuteri FN041 (viable count 1 × 10)9CFU/bar) probiotic powder; LGG group is administered with Lactobacillus rhamnosus GG (viable count 1 × 10)9CFU/bar) probiotic powder.
The inclusion criteria of the children patients are as follows: 1) atopic dermatitis having a skin damage area of 40% or less; 2) the infant patient and the parents know the information, and the parents sign an informed consent; 3) the compliance is good; 4) patients who do not receive glucocorticoid, immunomodulator and antihistamine medicine treatment within 2 weeks before treatment.
Exclusion criteria were: 1) patients with organic, immunological, infectious, hematological diseases; 2) those who had been treated systemically with phototherapy, cytostatics, glucocorticoids, immunosuppressants within 2 weeks prior to observation; 3) no other trials were performed.
In the whole test process, the lactobacillus reuteri FN041 and the lactobacillus rhamnosus GG are taken as probiotic bacteria powder, and can be directly taken or taken with warm water (not more than 37 ℃) with the dosage of 1 strip/day.
The trial preparation period was 2 weeks, and the clinical trial period was 8 weeks, for a total of 10 weeks.
A preparation period: sick children were contacted 2 weeks prior to the trial, and the number of persons intentionally participating in the trial was counted, and they and parents or other guardians were explained about the nature and content of the trial, and informed consent was made while coordinating the time of the hospital and doctor, and the materials needed to prepare the trial.
And (3) a clinical trial period: the children who had been diagnosed by the doctor, voluntarily, and agreed to participate in the trial by the guardian were administered placebo and probiotic (the outer package was completely identical) for 8 weeks. Before the experiment, children and parents were educated in a centralized way, which shows that the reason for the AD and diet are measures for avoiding the AD in life, and hope that the children and the parents adhere to the corresponding principles during the experiment.
Diagnosis is performed after the end of the preparation period, at the beginning and at the end of the clinical trial. Recording the skin damage area, clinical characteristics, pruritus, sleep loss degree, score and other observation indexes, inquiring the compliance, and recording adverse reactions, wherein the specific experimental flow is shown in figure 4. The score index was used to assess the extent of mild AD, including:
1. area was assessed (rule 9), max score 100, and differences between infants under 2 years of age and adults were noted.
2. Six clinical features were evaluated: erythema/color deepening; edema/papules; oozing/crusting; denudation; lichenification/prurigo; and (5) drying.
The first 5 individual, average representative sites were evaluated and the uninvolved sites were evaluated dry.
Grading scale: 0-3, 0 ═ none; 1 is mild; 2 is moderate; with 3 being severe, the maximum score is 18 points.
3. Two visual analog scales: patients evaluated the degree of itching and sleep loss ties before the last 3 days (late).
The first two terms are objective SCORADs, which can be used independently, with a maximum score of 83 points, plus a maximum score of 103 points for term 3.
As shown in fig. 5, 5 final children were excluded and 75 completed the clinical study, and were administered probiotic powder and placebo for 8 weeks, respectively, and the score of lactobacillus reuteri FN041 was significantly reduced (P <0.05) after evaluation compared to that before administration of the probiotic, and the symptoms of the patients were significantly improved. Three groups of sodad significantly differed during the initial phase of intervention. Both probiotics at the end of the intervention period could alleviate the score, with LGG treatment reducing score by 16% per month, while after GDMCC60546 treatment score reduction by 28% was achieved.
Example 4: preparation method of fermented fruit and vegetable beverage containing lactobacillus reuteri FN041
The method comprises the following specific steps:
cleaning fresh vegetables and fruits, squeezing to obtain juice, sterilizing at 140 deg.C for 2 s, immediately cooling to 42 deg.C, and pressing at 10 deg.C6Inoculating Lactobacillus reuteri FN041 into CFU/mL fruit and vegetable juice, and fermenting the inoculated fruit and vegetable juice at 42 deg.C for 16 hr to obtain juice containing Lactobacillus reuteri FN041Fermented fruit and vegetable beverage containing live Lactobacillus reuteri FN041 is provided.
Through detection, the pH value of the fermented fruit and vegetable beverage containing the live lactobacillus reuteri FN041 is 3.6, and the number of the live bacteria can reach l.5 multiplied by 109CFU/mL。
The fermented fruit and vegetable beverage containing the live lactobacillus reuteri FN041 is continuously taken by children patients with atopic dermatitis for one week, so that the swelling of the affected parts of the dermatitis of the patients can be effectively relieved, the SCORAD index of the patients can be effectively reduced, and the symptoms and the life quality of the patients are obviously improved.
Example 5: preparation of fermented milk containing Lactobacillus reuteri FN041
The method comprises the following specific steps:
adding 2% casein peptide into raw milk (skim milk, fresh milk, reconstituted milk and the like), carrying out high-strength heat treatment at 95 ℃, 20min or 140 ℃ for 2 seconds, cooling to 40 ℃, inoculating 3-5% of lactobacillus reuteri FN041 in volume percentage to the sterilized raw milk, inoculating 3-5% of lactobacillus bulgaricus or streptococcus thermophilus which can be symbiotically fermented and used for preparing the commercial starter of the yoghourt in volume percentage to the raw milk inoculated with the lactobacillus reuteri FN041, and carrying out mixed fermentation on the inoculated raw milk at 42 ℃ for 4 hours to obtain the fermented milk containing the viable lactobacillus reuteri FN 041.
Through detection, the titration acidity of the fermented milk containing the live bacteria of the lactobacillus reuteri FN041 reaches 75 DEG T, and the number of the live bacteria reaches 1 × 109CFU/mL。
The fermented milk containing the live lactobacillus reuteri FN041 is continuously taken by atopic dermatitis patients for one week, so that the swelling of the dermatitis affected parts of the patients can be effectively relieved, the SCORAD index of the patients can be effectively reduced, and the symptoms and the life quality of the patients are obviously improved.
Although the present invention has been described with reference to the preferred embodiments, it should be understood that various changes and modifications can be made therein by those skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims.
Claims (10)
1. Use of lactobacillus reuteri (lactobacillus reuteri) FN041 in the manufacture of a product for the prevention and/or treatment of atopic dermatitis in a target population; the target population is pregnant women, lactating women and/or children.
2. The use according to claim 1, wherein the prevention and/or treatment of atopic dermatitis comprises any one of (a) to (d):
(a) relieving inflammatory reaction and inflammatory hyperplasia;
(b) relieving the swelling degree of the affected part;
(c) reducing the number of mast cells and eosinophils;
(d) improve the infiltration degree of inflammatory cells of the mice.
3. The use of claim 1 or 2, wherein the gestational period is from week 14 of gestation until birth of the infant; the lactation period is within 12 months from the birth of the infant; the target child is no older than 12 years.
4. Use according to any one of claims 1 to 3, wherein the product includes, but is not limited to, a food product, a pharmaceutical or pharmaceutical composition and/or a nutraceutical.
5. The use according to any one of claims 1 to 4, wherein the viable count of the product is not less than 1 x 106CFU/day doses were given to children.
6. The use according to any one of claims 1 to 5, wherein the form of Lactobacillus reuteri comprises viable cells, inactivated cells or fermentation products or metabolites of Lactobacillus reuteri, or a mixture of any of the above forms.
7. The use of any one of claims 1 to 6, wherein the product is in a dosage form including, but not limited to: tablet, granule, capsule, powder, liquid or jelly.
8. The use of any one of claims 1 to 7, wherein the medicament or pharmaceutical composition further comprises a pharmaceutically acceptable excipient; the pharmaceutically acceptable excipient refers to any diluent, adjuvant and/or carrier that can be used in the pharmaceutical field.
9. The use according to any one of claims 1 to 8, wherein the food product comprises a dairy product, a soy product, a fruit and vegetable product or a beverage produced using a fermentation broth comprising Lactobacillus reuteri; or the food comprises a solid beverage, tablet, soft candy and drops containing the lactobacillus reuteri.
10. The use according to any one of claims 1 to 9, wherein the food or health product further comprises conventional adjuvants including one or more of fillers, flavoring agents, binders, disintegrants, lubricants, antacids, and fortifiers.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111233636.7A CN113841737A (en) | 2021-10-22 | 2021-10-22 | Application of lactobacillus reuteri strain derived from breast milk to prevention and treatment of atopic dermatitis |
| PCT/CN2022/126353 WO2023066328A1 (en) | 2021-10-22 | 2022-10-20 | Use of lactobacillus reuteri from breast milk in prevention and treatment of atopic dermatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111233636.7A CN113841737A (en) | 2021-10-22 | 2021-10-22 | Application of lactobacillus reuteri strain derived from breast milk to prevention and treatment of atopic dermatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113841737A true CN113841737A (en) | 2021-12-28 |
Family
ID=78982935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111233636.7A Pending CN113841737A (en) | 2021-10-22 | 2021-10-22 | Application of lactobacillus reuteri strain derived from breast milk to prevention and treatment of atopic dermatitis |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113841737A (en) |
| WO (1) | WO2023066328A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023066328A1 (en) * | 2021-10-22 | 2023-04-27 | 青岛大学 | Use of lactobacillus reuteri from breast milk in prevention and treatment of atopic dermatitis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111265553A (en) * | 2020-01-23 | 2020-06-12 | 湖南菲勒生物技术有限公司 | Application of lactobacillus reuteri from breast milk to adjustment of maternal and infant immune functions |
| CN113073066A (en) * | 2021-04-16 | 2021-07-06 | 北京华元生物技术研究院 | Lactobacillus reuteri and application, composition, medicine and food thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103114051A (en) * | 2012-11-15 | 2013-05-22 | 上海交大昂立股份有限公司 | Roy bacterium lacticum and application thereof |
| CN105087437A (en) * | 2015-08-13 | 2015-11-25 | 吴前进 | 3-hydroxy-propionaldehyde high-producing strain and application thereof in preventing and treating skin infection in mammals |
| CN109645492A (en) * | 2019-01-28 | 2019-04-19 | 新萃斯生物科技(上海)有限公司 | It is a kind of with the child form composite formula and preparation method thereof for controlling allergy in advance |
| CN110205261B (en) * | 2019-05-10 | 2020-08-04 | 湖南菲勒生物技术有限公司 | Application of breast milk-derived lactobacillus reuteri in reducing blood fat and regulating lipid metabolism rhythm |
| CN113841737A (en) * | 2021-10-22 | 2021-12-28 | 青岛大学 | Application of lactobacillus reuteri strain derived from breast milk to prevention and treatment of atopic dermatitis |
-
2021
- 2021-10-22 CN CN202111233636.7A patent/CN113841737A/en active Pending
-
2022
- 2022-10-20 WO PCT/CN2022/126353 patent/WO2023066328A1/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111265553A (en) * | 2020-01-23 | 2020-06-12 | 湖南菲勒生物技术有限公司 | Application of lactobacillus reuteri from breast milk to adjustment of maternal and infant immune functions |
| CN113073066A (en) * | 2021-04-16 | 2021-07-06 | 北京华元生物技术研究院 | Lactobacillus reuteri and application, composition, medicine and food thereof |
Non-Patent Citations (1)
| Title |
|---|
| 阿虎医考研究组: "《诊断学速记》", vol. 3, 中国医药科技出版社, pages: 281 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023066328A1 (en) * | 2021-10-22 | 2023-04-27 | 青岛大学 | Use of lactobacillus reuteri from breast milk in prevention and treatment of atopic dermatitis |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023066328A1 (en) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1482959B1 (en) | Compositions for treatment of skin disorders | |
| JP6148251B2 (en) | Pharmaceutical composition for the treatment or prevention of allergic diseases including dead bacteria of Lactobacillus acidophilus erby | |
| US20170216375A1 (en) | Neonatal Microbiome Supplementation | |
| JP4212838B2 (en) | Antiallergic agent | |
| KR102475432B1 (en) | Novel probiotic formulation for modulating intestinal immunity | |
| JP5925274B2 (en) | Endometriosis prevention and / or amelioration agent and food and beverage composition comprising the same | |
| JP2022504792A (en) | How to treat inflammatory diseases and related infections | |
| US20220257676A1 (en) | Agent for regulating female hormone secretion and agent for alleviating unpleasant symptoms | |
| JP2011501664A (en) | Probiotics used to relieve symptoms associated with digestive disorders | |
| CN113841737A (en) | Application of lactobacillus reuteri strain derived from breast milk to prevention and treatment of atopic dermatitis | |
| Yamashita et al. | Intake safety of Lactobacillus helveticus SBT2171 and its effects on nasal and ocular symptoms associated with mites and house dust: An open-label study and a randomized, double-blind, placebo-controlled, parallel group study | |
| CN116617272A (en) | Application of lactobacillus reuteri in preparing functional product for preventing and treating acute radiation intestinal injury | |
| CN112569263B (en) | Composite probiotics freeze-dried powder | |
| CN112546074B (en) | Bifidobacterium breve capable of inhibiting release of IL-23 and Th17 axis-related inflammatory factors and application thereof | |
| CN116744950A (en) | Methods for preventing, delaying or ameliorating atopic diseases | |
| JPH09263539A (en) | Therapeutic agent for dermatopathy having antifungal action | |
| Hamed et al. | The effect of probiotics on reducing duration of hospitalization in infants with indirect hyperbilirubinemia | |
| US20190388484A1 (en) | Lactobacillus reuteri gmnl-263 for improving hypertension and its compositions thereof | |
| TW201943852A (en) | Bacterial strain of Lactobacillus reuteri GMNL-263 capable of improving hypertension and composition thereof for lowering blood pressure by inhibiting pro-inflammatory cytokines IL-1<beta> and improving growth of Bifidobacterium | |
| CN116077607B (en) | Probiotic fermented traditional Chinese medicine composition for resisting helicobacter pylori infection and application thereof | |
| US20240131089A1 (en) | Composition and Use Thereof | |
| US20200405783A1 (en) | Probiotic for the treatment of psoriasis | |
| CN106974940A (en) | Application of the heavy wall mushroom probiotics in fat and its relevant disease is treated and prevented | |
| CN116731905A (en) | Probiotic composition and application thereof | |
| BG4294U1 (en) | Biologically active product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20230322 Address after: Room 2505, Unit 2, Building 3, No. 186, Liaoning Road, Shibei District, Qingdao, Shandong Province, 266000 Applicant after: Shangpin Health Technology (Qingdao) Co.,Ltd. Applicant after: QINGDAO University Address before: 266071 Ningxia Road, Laoshan District, Qingdao, Shandong Province, No. 308 Applicant before: QINGDAO University |